Royal Bank of Canada
FATE icon

Royal Bank of Canada’s Fate Therapeutics FATE Stock Holding History

Royal Bank of Canada’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Sell
5,894
-3,608
-38% -$4.39K ﹤0.01% 6312
2025
Q4 		$9K Sell
9,502
-177,833
-95% -$214K ﹤0.01% 6458
2025
Q3 		$236K Buy
187,335
+37,383
+25% +$40.3K ﹤0.01% 4990
2025
Q2 		$168K Buy
149,952
+141,377
+1,649% +$164K ﹤0.01% 5282
2025
Q1 		$6K Sell
8,575
-5,990
-41% -$7.34K ﹤0.01% 6298
2024
Q4 		$24K Buy
14,565
+2,394
+20% +$6.03K ﹤0.01% 6038
2024
Q3 		$43K Buy
12,171
+2,339
+24% +$9.1K ﹤0.01% 5773
2024
Q2 		$32K Buy
9,832
+7,834
+392% +$34.3K ﹤0.01% 5858
2024
Q1 		$15K Sell
1,998
-25,190
-93% -$156K ﹤0.01% 6030
2023
Q4 		$102K Buy
27,188
+12,832
+89% +$30.3K ﹤0.01% 5608
2023
Q3 		$30K Buy
14,356
+3,863
+37% +$12.8K ﹤0.01% 6024
2023
Q2 		$49K Buy
10,493
+3,382
+48% +$18.7K ﹤0.01% 5789
2023
Q1 		$41K Sell
7,111
-16,021
-69% -$96.7K ﹤0.01% 5716
2022
Q4 		$234K Buy
23,132
+18,557
+406% +$349K ﹤0.01% 4738
2022
Q3 		$103K Buy
4,575
+556
+14% +$16.1K ﹤0.01% 5288
2022
Q2 		$100K Sell
4,019
-7,157
-64% -$197K ﹤0.01% 5330
2022
Q1 		$433K Sell
11,176
-15,772
-59% -$611K ﹤0.01% 4385
2021
Q4 		$1.58M Buy
26,948
+16,278
+153% +$923K ﹤0.01% 3368
2021
Q3 		$633K Sell
10,670
-139,818
-93% -$11M ﹤0.01% 4150
2021
Q2 		$13.1M Buy
150,488
+116,185
+339% +$9.36M ﹤0.01% 1649
2021
Q1 		$2.83M Buy
34,303
+34,105
+17,225% +$3.27M ﹤0.01% 2727
2020
Q4 		$18K Sell
198
-679
-77% -$42.2K ﹤0.01% 6107
2020
Q3 		$35K Buy
877
+416
+90% +$14.5K ﹤0.01% 5494
2020
Q2 		$16K Buy
461
+180
+64% +$5.37K ﹤0.01% 5674
2020
Q1 		$6K Sell
281
-1,882
-87% -$47.6K ﹤0.01% 5976
2019
Q4 		$42K Buy
+2,163
New +$34.4K ﹤0.01% 5525
2019
Q3 		– Sell
-6
Closed – – 6811
2019
Q2 		$0 Buy
+6
New +$108 ﹤0.01% 6950
2018
Q4 		– Sell
-1,451
Closed -$24K – 6855
2018
Q3 		$24K Buy
1,451
+1,352
+1,366% +$16K ﹤0.01% 5579
2018
Q2 		$1K Buy
+99
New +$1.09K ﹤0.01% 6347
2018
Q1 		– Sell
-70
Closed – – 6464
2017
Q4 		$0 Sell
70
-3,355
-98% -$15K ﹤0.01% 6628
2017
Q3 		$14K Buy
+3,425
New +$11.6K ﹤0.01% 6133
2017
Q2 		– Sell
-6
Closed – – 6614
2017
Q1 		$0 Buy
+6
New +$22 ﹤0.01% 6654
2015
Q4 		– Sell
-103
Closed -$1K – 6688
2015
Q3 		$1K Sell
103
-300
-74% -$2.05K ﹤0.01% 6478
2015
Q2 		$3K Buy
+403
New +$2.41K ﹤0.01% 6313

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's FATE Position: Q1 2026 in Review

Royal Bank of Canada reduced its Fate Therapeutics (FATE) stake by 38% in Q1 2026, selling an estimated $4.39K and leaving 5,894 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6312.

Royal Bank of Canada first reported a position in FATE in Q2 2015 and has held it in 34 quarters since. The position peaked at $13.1M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Royal Bank of Canada held 5,894 shares of Fate Therapeutics worth $7K as of Q1 2026.
  • Royal Bank of Canada sold 3,608 Fate Therapeutics shares in Q1 2026, an estimated $4.39K.
  • Fate Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6312 holding.
  • Royal Bank of Canada first reported a position in Fate Therapeutics in Q2 2015 and has held it in 34 quarters since.
  • Royal Bank of Canada's Fate Therapeutics position peaked at $13.1M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.